UC & Bladder Cancer Testing (MUrine)

85% of bladder cancer patients exhibit painless hematuria as an initial symptom, where blood is present in the urine. Traditional testing methodologies such as imaging and cytology has been shown to have low sensitivity, prompting better tools to screen for bladder cancer. However, this traditionally comes in the form of cystoscopies, which are highly invasive, uncomfortable, and requires anesthesia. Murine sits in the middle, harnessing DNA methylation biomarkers in urine to determine whether there is further need for cystoscopy in high-risk cases, or regular cytology examinations in low-risk cases. It is non-invasive and painless, which prevents unnecessary invasive cystoscopies in cases where painless hematuria is not necessarily an indicator of bladder cancer.